title: [Drug (statine)-induced hepatitis].
abstract: In the article is presented the case of development of medicinal hepatitis as result of irrational use of statin treatment at patient with Ischemic heart disease and nonalcoholic Fatty Liver Disease against morbid obesity. The clinical observation reflects the necessity of usage of liver protectors in prevention of possible side effects of hypolipidemic statin treatment and emphasizes the advantage of double cholesterol inhibition.
authors: L B
authors: LB
authors: Lazebnik
authors: L A
authors: LA
authors: Zvenigorodskaia
authors: S G
authors: SG
authors: Khomeriki
authors: L I
authors: LI
authors: Efremov
authors: E A
authors: EA
authors: Cherkashova
mesh_terms: D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D002756:Cholagogues and Choleretics / Q000008:administration & dosage / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000188:drug therapy; D009765:Obesity / Q000097:blood / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D002756:Cholagogues and Choleretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014580:Ursodeoxycholic Acid; D002784:Cholesterol